OncoMatch/Clinical Trials/NCT07073833
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Is NCT07073833 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including IBR900 cell and rituximab for relapsed/refractory b-cell non-hodgkin lymphoma.
Treatment: IBR900 cell · rituximab — This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory B-cell non Hodgkin lymphoma (NHL); Phase Ib is the dose expansion stage, which is divided into two parts: monotherapy expansion (queue 1) and combination expansion (queue 2). The monotherapy expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma, while the combination expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection combined with CD20 monoclonal antibodies in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 positive (CD20 positive)
CD20 positive B-cell non Hodgkin's lymphoma
Allowed: MYC rearrangement
high-grade B-cell lymphoma with MYC and BCL2 rearrangements, high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Allowed: BCL2 rearrangement
high-grade B-cell lymphoma with MYC and BCL2 rearrangements, high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Allowed: BCL6 rearrangement
high-grade B-cell lymphoma with MYC/BCL2/BCL6 rearrangements
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline
previous treatment of anthracycline containing drugs
Must have received: CD20-targeted therapy (rituximab)
previous treatment of rituximab or other CD20 targeted therapies
Must have received: anti-CD20 monoclonal antibody
At least one regimen contains anti-CD20 monoclonal antibody monotherapy or combination therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have received allogeneic hematopoietic stem cell transplantation
Cannot have received: other organ transplantation
other organ transplantation
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 100 days before the first dose
autologous hematopoietic stem cell transplantation within 100 days before the first dose
Lab requirements
Cardiac function
LVEF ≤ 55%; NYHA Grade II or above congestive heart failure or active heart disease; Serious arrhythmias that require treatment (excluding atrial fibrillation and paroxysmal supraventricular tachycardia that have been determined by the researchers to have no impact on the trial); QTc interval ≥ 450ms for males and ≥ 470ms for females; Within 6 months prior to administration, there has been a myocardial infarction or bypass or stent surgery; Other heart diseases deemed unsuitable for inclusion by researchers
The patient's heart meets any of the following conditions: left ventricular ejection fraction (LVEF) ≤ 55%; New York Heart Association (NYHA) Grade II or above congestive heart failure or active heart disease; Serious arrhythmias that require treatment (excluding atrial fibrillation and paroxysmal supraventricular tachycardia that have been determined by the researchers to have no impact on the trial); QTc interval ≥ 450ms for males and ≥ 470ms for females; Within 6 months prior to administration, there has been a myocardial infarction or bypass or stent surgery; Other heart diseases deemed unsuitable for inclusion by researchers
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07073833 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, other organ transplantation, autologous hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages